Stanford Study Finds Migraine Patients Treated with OnabotA tend to Elect Extended Treatment What are the main findings?

Response: We found that patients on average received 2 years of onabotA treatment (mean 7.60 treatments). We also conducted a time-to-event analysis that suggested that when duration in our database is controlled for, about a quarter of patients would complete over 7 years of treatment (29 treatments). While we had worried that distance and economic factors would limit treatment, reassuringly, distance to treatment facility and zip code income quartile were not associated with differences in the number of onabotA treatments received. What should readers take away from your report?

Response: Prior to our paper, the largest and longest study of onabotA treatment was only up to two years duration. Our work suggests that onabotA is a treatment that patients elect to continue for an extended period of time, with our time-to-event survival analysis suggesting that over a quarter of patients would continue it for more than seven years. Critically, distance and zip code income quartile, a surrogate for insurance/access to care, did not affect duration of treatment. What recommendations do you have for future research as a result of this study?

Response: Since our work measured persistence to onabotA treatments and not efficacy or side effects, future research should focus on outcomes and tolerability of onabotA over periods of time of at least five years to reflect a sufficiently long-term patient experience with onabotA.

I have no disclosures.

Citation: Leon S Moskatel, Anna Graber-Naidich, Zihuai He, Niushen Zhang, Long-term persistence to OnabotulinumtoxinA to prevent chronic migraine: Results from 11 years of patient data from a tertiary headache center, Pain Medicine, 2024;, pnae020,

The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on March 29, 2024 by